Skip to main content
Clinical Trials/ISRCTN46445413
ISRCTN46445413
Completed
Phase 3

Prospective, randomised, double-blind, placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with inflammatory osteoarthritis (OA) of the hands

Charité - University of Medicine, Berlin (Germany)0 sites510 target enrollmentJune 9, 2011

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Refractory inflammatory hand osteoarthritis
Sponsor
Charité - University of Medicine, Berlin (Germany)
Enrollment
510
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

2014 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/25348033 protocol

Registry
who.int
Start Date
June 9, 2011
End Date
July 5, 2018
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Charité - University of Medicine, Berlin (Germany)

Eligibility Criteria

Inclusion Criteria

  • 1\. Men and women from 40 to 80 years
  • 2\. Presence of clinical hand OA according to American College of Rheumatology (ACR) criteria
  • 3\. Conforming to the ACR criteria for hand OA with recent X ray, dating less than 6 months ago, X ray of the hands showing radiological signs of digital OA in one or more joints as defined by grades 2 or higher, per Kellgren and Lawrence scale or alternatively using the Kallman method or alternativly using the Verbruggen Score;
  • 4\. Symptomatic digital OA with more than three finger joints for more than 3 months (at least every other day) despite taking analgesics and non\-steroidal anti\-inflammatory drugs (NSAIDs)
  • 5\. Pain above 35 mm as evaluated by the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) \-Visual Analogue Scale( VAS) (0 \- 100 mm)
  • 6\. Function as co\-primary clinical outcome with \= 9 using the AUSCAN LK function subscale, or \= 225 F (out of maximum of 800\) on the AUSCAN VA function subscale

Exclusion Criteria

  • 1\. Patients who have already been treated with HCQ
  • 2\. Existence of painful syndrome of upper limbs likely to interfere with the monitoring of pain
  • 3\. Patients suffering or having suffered from secondary OA after one of the following diseases (e.g. infectious arthritis, acromegaly, ochronosis, haemochromatosis, gout, etc.) or inflammatory joint diseases
  • 4\. Any unstable medical condition which would put the patient at an unacceptable risk
  • 5\. Planned Surgery
  • 6\. Local injection with glucocorticoids or other medications within the previous three months
  • 7\. Oral glucocorticoids
  • 8\. Presence of retinopathy

Outcomes

Primary Outcomes

Not specified

Similar Trials